Secukinumab therapy for paediatric patients with various phenotypes of congenital ichthyosis.

Abstract

This case series demonstrate that secukinumab therapy for for paediatric patients with congenital ichthyosis is safe and have variable efficacy, similar to results from clinical trial in adult patients. Good response is seen in patients with the erythrodermic phenotypes, namely congenital ichthyosiform erythroderma and Netherton syndrome, with minor response seen in lamellar ichthyosis phenotypes. Clinical data is overall lacking for paediatric population, and this study adds some insights to the existing research.